LEADER 02590oam  2200589 a 450 
001 9910690658903321
005 20040429091642.0
035   $a(CKB)5470000002339723
035   $a(OCoLC)41321493
035 9 $aocm41321493
035   $a(OCoLC)995470000002339723
035   $a(EXLCZ)995470000002339723
100   $a19990507d1999      ua             0
101 0 $aeng
135   $aurunu|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aRelative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer$b[electronic resource]
210  1$a[Rockville, Md.] :$c[U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research],$d[1999]
225 1 $aEvidence report/technology assessment. Summary ;$vno. 4
225 1 $aAHCPR publication ;$vno. 99-E011
300   $aTitle from title screen (viewed on Apr. 29, 2004).
300   $a"January 1999."
300   $a"The full evidence report from which this summary was taken was prepared by the Evaluation Technology Center, an AHCPR Evidence-based Practice Center of the Blue Cross and Blue Shield Association, Chicago, Illinois, under contract no. 290-97-0015."
606   $aProstate$xCancer$xHormone therapy
606   $aAntiandrogens$xTherapeutic use
606   $aAndrogen Antagonists$xtherapeutic use
606   $aCost-Benefit Analysis
606   $aGonadotropin-Releasing Hormone$xantagonists & inhibitors
606   $aOutcome Assessment, Health Care
606   $aProstatic Neoplasms$xdrug therapy
606   $aRandomized Controlled Trials as Topic
615  0$aProstate$xCancer$xHormone therapy.
615  0$aAntiandrogens$xTherapeutic use.
615  2$aAndrogen Antagonists$xtherapeutic use.
615  2$aCost-Benefit Analysis.
615  2$aGonadotropin-Releasing Hormone$xantagonists & inhibitors.
615  2$aOutcome Assessment, Health Care.
615  2$aProstatic Neoplasms$xdrug therapy.
615  2$aRandomized Controlled Trials as Topic.
712 02$aUnited States.$bAgency for Health Care Policy and Research.
712 02$aBlue Cross and Blue Shield Association.$bTechnology Evaluation Center.
801  0$bMMU
801  1$bMMU
801  2$bOCL
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910690658903321
996   $aRelative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer$93113110
997   $aUNINA